Thanks for your comments skint, I have been a long follower of SBP as you probably know. This is definitely a positive development for the company and given the screening that Ngourney would have done, there is every chance this treatment will have a positive outcome for this patient. This result, in an American hospital and under the watchful eye of the FDA, will be a massive boost for the profile and reputation of the company. Lets not forget, they already have TWO Orphan Drugs status' so once they get the phase II trials completed and prove efficiacy, they will be well on their way...
SBP
solbec pharmaceuticals limited
